Horizon Therapeutics plc HZNP, previously known as Horizon Pharma plc, reported second-quarter 2019 adjusted earnings of 49 cents per share, which beat the Zacks Consensus Estimate of 38 cents and increased from 48 cents reported in the year-ago quarter.
The company reported quarterly sales of $320.6 million, up 6% year over year. The top line also beat the Zacks Consensus Estimate of $299 million.
On May 2, 2019, shareholders of the company approved the change of the company’s name to Horizon Therapeutics. This move caters to the company’s long-term strategy to develop and commercialize innovative medicines addressing rare diseases, which currently have very few effective treatment options.
Horizon Therapeutics’ share price has rallied 35.6% year to date against the industry’s decline of 2.1%.
Quarter in Detail
The company realigned its structure to operate two separate businesses. Thus, with effect from the second quarter of 2018, the company has been reporting financial results in two separate segments — the orphan and rheumatology segment, and the Inflammation (previously known as the primary care segment) segment. Sales of the orphan and rheumatology segment were $223.5 million, up 11% from the prior-year quarter’s figure, driven by continued strong growth of Krystexxa, Procysbi, Rayos and Actimmune. Krystexxa sales increased 36% year over year to $79.8 million. Beginning January 2019, the company no longer recognizes certain ex-U.S. sales of Ravicti, Buphenyl and Lodotra following the divestiture of those rights in 2018.
Second-quarter 2019 net sales of the Inflammation segment were $97.1 million, down 4% year over year.
Adjusted R&D expenses and adjusted SG&A expenses were 6.9% and 45.4% of net sales, respectively.
The company now expects full-year 2019 net sales to be $1.28-$1.30 billion, up from the previous guidance of $1.26-$1.28 billion.
Other Pipeline Updates
The company’s pipeline candidate teprotumumab is being developed for the treatment of thyroid eye disease (TED).
In July, the company submitted a Biologics License Application (BLA) for teprotumumab for the treatment of active TED to the FDA. Horizon Therapeuticshas requested a Priority Review status for the application, which, if granted, could result in a six-month review process. If approved, teprotumumab would be the first and only approved treatment for active TED.
Horizon Therapeutics is evaluating the use of methotrexate to enhance the response rate to Krystexxa through the MIRROR study in adults living with uncontrolled gout. The MIRROR study is designed to support the potential for registration of Krystexxa and was initiated in June 2019.
In July 2019, the FDA accepted the new drug application (NDA) for Procysbi delayed-release oral granules in packets. If approved, this new dosage form would provide another administration option to patients, in addition to the currently available Procysbi delayed-release capsules, which are FDA-approved for children aged one year or older and adults living with nephropathic cystinosis.
Horizon Therapeutics plans to initiate a clinical trial in the second half of 2019, evaluating the effect of Krystexxa on serum uric acid levels in kidney transplant patients with uncontrolled gout.
Horizon Pharma Public Limited Company Price, Consensus and EPS Surprise
Horizon Pharma Public Limited Company price-consensus-eps-surprise-chart | Horizon Pharma Public Limited Company Quote
Zacks Rank & Stocks to Consider
Horizon Therapeutics currently has a Zacks Rank #3 (Hold).
Some better-ranked stocks are Acorda Therapeutics Inc. ACOR, Axovant Sciences Ltd. AXGT and Epizyme Inc. EPZM. While Acorda and Axovant carry a Zacks Rank #1 (Strong Buy), Epizyme carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Acorda’s loss per share estimates have narrowed from $3.59 to $2.74 for 2019 in the past 60 days. The company delivered a positive earnings surprise in the trailing four quarters, the average being 69.68%.
Axovant’s loss per share estimates have narrowed from $7.00 to $5.34 for 2019 and from $6.48 to $3.59 for 2020 in the past 60 days.
Epizyme’s loss per share estimates have narrowed from $1.80 to $1.79 for 2020 in the past 90 days. The company delivered a positive earnings surprise in the trailing four quarters, the average being 22.15%.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity. A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 7 stocks to watch. The report is only available for a limited time.
See 7 breakthrough stocks now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Epizyme, Inc. (EPZM) : Free Stock Analysis Report
Horizon Pharma Public Limited Company (HZNP) : Free Stock Analysis Report
Acorda Therapeutics, Inc. (ACOR) : Free Stock Analysis Report
Axovant Sciences Ltd. (AXGT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research